A clinical study of triple combinations to evaluate IPI-549 in combination with AB928 and chemotherapy in triple negative breast cancer and ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs AB-928 (Primary) ; IPI 549 (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Therapeutic Use
- Sponsors Arcus Biosciences
- 07 Jan 2019 According to an Infinity Pharmaceuticals media release, the company expects to initiate this study in 1H 2019.
- 16 Nov 2018 New trial record
- 05 Nov 2018 According to an Infinity Pharmaceuticals media release, top line results from this study are expected in 2019.